Swan Genomics is developing a plasmonic nanoantenna-based single-molecule DNA sequencing platform that addresses a fundamental bottleneck in genomic medicine: the cost, speed, and accessibility of sequencing at clinical and research scale. While the platform is pre-revenue with a product launch hori

HeadFirst is developing a rapid, saliva-based concussion screening test for point-of-care use, delivering results in under 10 minutes without lab infrastructure. Our core breakthrough is proprietary chemistry that enables visual detection of low-concentration biomarkers in saliva on a portable, single-use assay, which has historically required instrumentation. We are initially applying this to traumatic brain injury given the significant unmet need, enabling real-time decision-making in athletic, clinical, and military settings. On the commercial side, we are pursuing a B2B distribution strategy with sports organizations, clinics, and healthcare providers, supported by early LOIs and pilot programs to drive adoption.